A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions

被引:27
作者
Holloway, Andrew J.
Diyagama, Dileepa S.
Opeskin, Ken
Creaney, Jenette
Robinson, Bruce W. S.
Lake, Richard A.
Bowtell, David D. L.
机构
[1] Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia
[2] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia
[3] Peter MacCallum Canc Ctr, Ian Potter Ctr Canc Genom & Predict Med, Melbourne, Vic, Australia
[4] St Vincents Hosp, Dept Anat Pathol, Fitzroy, Vic 3065, Australia
[5] Univ Western Australia, Sch Med & Pharmacol, Crawley, Australia
[6] Queen Elizabeth II Med Ctr, Western Australian Inst Med Res, Nedlands, WA, Australia
关键词
D O I
10.1158/1078-0432.CCR-06-1027
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Patients with malignant mesothelioma or adenocarcinoma of the lung often present with respiratory complications associated with a malignant pleural effusion. Distinguishing between these malignancies is frequently problematic, as many of the clinical, cytologic, and histologic features of the diseases overlap. Following cytologic analysis of pleural effusions, subsequent confirmatory tissue biopsies involve increased patient morbidity and expense. We have therefore designed a gene expression - based test to classify the primary tumor causing a malignant pleural effusion, using cells collected from the effusion itself. Experimental Design: We have used microarray data for 190 lung adenocarcinomas and 33 malignant mesotheliomas to identify genes differentially expressed between the two diseases. Genes expressed in normal mesothelial cells were removed, allowing the development of a PCR-based test to measure the expression of genes that discriminate between mesothelioma and lung adenocarcinoma from cytology specimens. Results: Applying an real-time PCR - based assay involving 17 genes to 13 independent samples from biopsy-proven malignant mesothelioma and lung adenocarcinomas resulted in the correct identification of all samples. Conclusions: We have developed a test that is able to distinguish between lung adenocarcinoma and mesothelioma in cells collected from pleural effusions.
引用
收藏
页码:5129 / 5135
页数:7
相关论文
共 39 条
[1]   Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies [J].
Abutaily, AS ;
Addis, BJ ;
Roche, WR .
JOURNAL OF CLINICAL PATHOLOGY, 2002, 55 (09) :662-668
[2]   Differentiation of mesothelioma from adenocarcinoma in serous effusions: The role of hyaluronic acid and CD44 localization [J].
Afify, AM ;
Stern, R ;
Michael, CW .
DIAGNOSTIC CYTOPATHOLOGY, 2005, 32 (03) :145-150
[3]   Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic antigen) [J].
Blumenthal, RD ;
Hansen, HJ ;
Goldenberg, DM .
CANCER RESEARCH, 2005, 65 (19) :8809-8817
[4]   Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma [J].
Ceresoli, GL ;
Zucali, PA ;
Favaretto, AG ;
Grossi, F ;
Bidoli, P ;
Del Conte, G ;
Ceribelli, A ;
Bearz, A ;
Morenghi, E ;
Cavina, R ;
Marangolo, M ;
Parra, HJS ;
Santoro, A .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (09) :1443-1448
[5]   Asbestos and the pleura - A review [J].
Cugell, DW ;
Kamp, DW .
CHEST, 2004, 125 (03) :1103-1117
[6]  
DIBONITO L, 1992, ACTA CYTOL, V36, P329
[7]   Cluster analysis and display of genome-wide expression patterns [J].
Eisen, MB ;
Spellman, PT ;
Brown, PO ;
Botstein, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (25) :14863-14868
[8]  
Gordon GJ, 2002, CANCER RES, V62, P4963
[9]   Macroscopic, histologic, histochemical, immunohistochemical, and ultrastructural features of mesothelioma [J].
Hammar, Samuel P. .
ULTRASTRUCTURAL PATHOLOGY, 2006, 30 (1-2) :3-17
[10]   Monoclonal antibody MOC-31 reactivity as a marker for adenocarcinoma in cytologic preparations [J].
Hecht, JL ;
Pinkus, JL ;
Pinkus, GS .
CANCER CYTOPATHOLOGY, 2006, 108 (01) :56-59